Shares of Esperion Therapeutics, Inc. (NASDAQ:ESPR – Get Rating) shot up 3.3% during trading on Tuesday . The stock traded as high as $6.91 and last traded at $6.91. 115,696 shares traded hands during mid-day trading, a decline of 92% from the average session volume of 1,422,240 shares. The stock had previously closed at $6.69.
Wall Street Analyst Weigh In
Several brokerages have commented on ESPR. Morgan Stanley raised their price target on shares of Esperion Therapeutics from $7.00 to $9.00 and gave the company an "underweight" rating in a research report on Wednesday, November 2nd. StockNews.com raised shares of Esperion Therapeutics from a "sell" rating to a "hold" rating in a research report on Thursday, November 3rd. Two equities research analysts have rated the stock with a sell rating, two have assigned a hold rating and one has issued a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Hold" and a consensus price target of $11.20.
Get Esperion Therapeutics alerts:Esperion Therapeutics Stock Performance
The company's 50 day moving average is $6.54 and its 200 day moving average is $6.98.
Esperion Therapeutics (NASDAQ:ESPR – Get Rating) last announced its quarterly earnings results on Tuesday, November 1st. The biopharmaceutical company reported ($0.81) EPS for the quarter, topping the consensus estimate of ($0.93) by $0.12. The company had revenue of $18.98 million for the quarter, compared to analyst estimates of $19.83 million. Analysts predict that Esperion Therapeutics, Inc. will post -3.65 earnings per share for the current fiscal year.Insider Buying and Selling at Esperion Therapeutics
In other Esperion Therapeutics news, General Counsel Benjamin Looker sold 6,347 shares of Esperion Therapeutics stock in a transaction on Wednesday, January 18th. The shares were sold at an average price of $7.00, for a total value of $44,429.00. Following the transaction, the general counsel now directly owns 64,453 shares in the company, valued at $451,171. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. 3.30% of the stock is currently owned by company insiders.
Institutional Trading of Esperion Therapeutics
A number of institutional investors have recently added to or reduced their stakes in the stock. Wasatch Advisors Inc. boosted its holdings in Esperion Therapeutics by 27.6% during the first quarter. Wasatch Advisors Inc. now owns 8,147,380 shares of the biopharmaceutical company's stock worth $37,804,000 after buying an additional 1,761,117 shares in the last quarter. Vanguard Group Inc. boosted its holdings in Esperion Therapeutics by 19.4% during the first quarter. Vanguard Group Inc. now owns 4,491,530 shares of the biopharmaceutical company's stock worth $20,841,000 after buying an additional 730,091 shares in the last quarter. Millennium Management LLC boosted its holdings in Esperion Therapeutics by 116.8% during the second quarter. Millennium Management LLC now owns 2,706,290 shares of the biopharmaceutical company's stock worth $17,212,000 after buying an additional 1,457,952 shares in the last quarter. Ikarian Capital LLC purchased a new stake in Esperion Therapeutics during the second quarter worth about $13,067,000. Finally, State Street Corp boosted its holdings in Esperion Therapeutics by 23.2% during the third quarter. State Street Corp now owns 1,533,148 shares of the biopharmaceutical company's stock worth $10,272,000 after buying an additional 288,609 shares in the last quarter. Hedge funds and other institutional investors own 85.87% of the company's stock.
Esperion Therapeutics Company Profile
(Get Rating)
Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia.
Featured Articles
- Get a free copy of the StockNews.com research report on Esperion Therapeutics (ESPR)
- Intuit Is About To Make a Move, But Which Way?
- 3 Late January Earnings Plays With Pop Potential
- Low-Priced Stocks Still Paying Dividends
- Why is the Chipotle Stock Price Surging This Week?
- Is the Northrop Grumman Selloff an Opportunity?
Receive News & Ratings for Esperion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Esperion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.